Identification of Tumor Microenvironment-Related Prognostic Genes in Sarcoma

Overview

Journal Front Genet

Date 2021 Feb 18

PMID 33597971

Citations 8

Authors

Dongjun Dai

Lanyu Xie

Yongjie Shui

Jinfan Li

Qichun Wei

Affiliations

Soon will be listed here.

Abstract

Aim: Immune cells that infiltrate the tumor microenvironment (TME) are associated with cancer prognosis. The aim of the current study was to identify TME related gene signatures related to the prognosis of sarcoma (SARC) by using the data from The Cancer Genome Atlas (TCGA).

Methods: Immune and stromal scores were calculated by estimation of stromal and immune cells in malignant tumor tissues using expression data algorithms. The least absolute shrinkage and selection operator (lasso) based cox model was then used to select hub survival genes. A risk score model and nomogram were used to predict the overall survival of patients with SARC.

Results: We selected 255 patients with SARC for our analysis. The Kaplan-Meier method found that higher immune ( = 0.0018) or stromal scores ( = 0.0022) were associated with better prognosis of SARC. The estimated levels of CD4+ ( = 0.0012) and CD8+ T cells ( = 0.017) via the tumor immune estimation resource were higher in patients with SARC with better overall survival. We identified 393 upregulated genes and 108 downregulated genes ( < 0.05, fold change >4) intersecting between the immune and stromal scores based on differentially expressed gene (DEG) analysis. The univariate Cox analysis of each intersecting DEG and subsequent lasso-based Cox model identified 11 hub survival genes (, , , , , , , , , , and ). Then, a hub survival gene-based risk score gene signature was constructed; higher risk scores predicted worse SARC prognosis ( < 0.0001). A nomogram including the risk scores, immune/stromal scores and clinical factors showed a good prediction value for SARC overall survival (C-index = 0.716). Finally, connectivity mapping analysis identified that the histone deacetylase inhibitors trichostatin A and vorinostat might have the potential to reverse the harmful TME for patients with SARC.

Conclusion: The current study provided new indications for the association between the TME and SARC. Lists of TME related survival genes and potential therapeutic drugs were identified for SARC.

Citing Articles

Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.

Sutherland L, Lang J, Gonzalez-Juarbe N, Pickett B Curr Issues Mol Biol. 2024; 46(7):7114-7133.

PMID: 39057065 PMC: 11275280. DOI: 10.3390/cimb46070424.

Comprehensive bioinformatics analysis and cell line experiments revealed the important role of CDCA3 in sarcoma.

Li Y, Wu Z, Ding T, Zhang W, Guo H, Huang F Heliyon. 2024; 10(13):e32785.

PMID: 39035484 PMC: 11259814. DOI: 10.1016/j.heliyon.2024.e32785.

Bioinformatics Screen Reveals Gli-Mediated Hedgehog Signaling as an Associated Pathway to Poor Immune Infiltration of Dedifferentiated Liposarcoma.

Beadle E, Bennett N, Rhoades J Cancers (Basel). 2023; 15(13).

PMID: 37444470 PMC: 10341348. DOI: 10.3390/cancers15133360.

Comprehensive analysis of a novel cuproptosis-related lncRNA signature associated with prognosis and tumor matrix features to predict immunotherapy in soft tissue carcinoma.

Liu B, Pang K, Feng C, Liu Z, Li C, Zhang H Front Genet. 2022; 13:1063057.

PMID: 36568384 PMC: 9768346. DOI: 10.3389/fgene.2022.1063057.

The immune landscape of undifferentiated pleomorphic sarcoma.

Lazcano R, Barreto C, Salazar R, Carapeto F, Traweek R, Leung C Front Oncol. 2022; 12:1008484.

PMID: 36313661 PMC: 9597628. DOI: 10.3389/fonc.2022.1008484.

References

DAngelo S, Shoushtari A, Keohan M, Dickson M, Gounder M, Chi P . Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clin Cancer Res. 2016; 23(12):2972-2980. PMC: 5486863. DOI: 10.1158/1078-0432.CCR-16-2349. View

Ni J, Wu Y, Qi F, Li X, Yu S, Liu S . Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia. Front Oncol. 2020; 9:1509. PMC: 6990132. DOI: 10.3389/fonc.2019.01509. View

Hanahan D, Coussens L . Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21(3):309-22. DOI: 10.1016/j.ccr.2012.02.022. View

Hui J . Epidemiology and Etiology of Sarcomas. Surg Clin North Am. 2016; 96(5):901-14. DOI: 10.1016/j.suc.2016.05.005. View

Hong W, Yuan H, Gu Y, Liu M, Ji Y, Huang Z . Immune-related prognosis biomarkers associated with osteosarcoma microenvironment. Cancer Cell Int. 2020; 20:83. PMC: 7075043. DOI: 10.1186/s12935-020-1165-7. View

Ostroumov D, Fekete-Drimusz N, Saborowski M, Kuhnel F, Woller N . CD4 and CD8 T lymphocyte interplay in controlling tumor growth. Cell Mol Life Sci. 2017; 75(4):689-713. PMC: 5769828. DOI: 10.1007/s00018-017-2686-7. View

Musa A, Ghoraie L, Zhang S, Glazko G, Yli-Harja O, Dehmer M . A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform. 2017; 19(3):506-523. PMC: 5952941. DOI: 10.1093/bib/bbw112. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

Maki R, Jungbluth A, Gnjatic S, Schwartz G, DAdamo D, Keohan M . A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma. 2013; 2013:168145. PMC: 3608267. DOI: 10.1155/2013/168145. View

10.

Fan T, Zhu M, Wang L, Liu Y, Tian H, Zheng Y . Immune profile of the tumor microenvironment and the identification of a four-gene signature for lung adenocarcinoma. Aging (Albany NY). 2020; 13(2):2397-2417. PMC: 7880407. DOI: 10.18632/aging.202269. View

11.

Oike N, Kawashima H, Ogose A, Hotta T, Hatano H, Ariizumi T . Prognostic impact of the tumor immune microenvironment in synovial sarcoma. Cancer Sci. 2018; 109(10):3043-3054. PMC: 6172059. DOI: 10.1111/cas.13769. View

12.

Hull E, Montgomery M, Leyva K . HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases. Biomed Res Int. 2016; 2016:8797206. PMC: 4983322. DOI: 10.1155/2016/8797206. View

13.

Nie M, Pan X, Tao H, Xu M, Liu S, Sun W . Clinical and prognostic significance of in lung cancer. Oncol Lett. 2020; 19(6):3899-3906. PMC: 7202280. DOI: 10.3892/ol.2020.11478. View

14.

Hsu H, Chu C, Chang Y, Yu J, Chen C, Jian C . Six novel immunoglobulin genes as biomarkers for better prognosis in triple-negative breast cancer by gene co-expression network analysis. Sci Rep. 2019; 9(1):4484. PMC: 6418134. DOI: 10.1038/s41598-019-40826-w. View

15.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

16.

Toulmonde M, Penel N, Adam J, Chevreau C, Blay J, Cesne A . Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncol. 2017; 4(1):93-97. PMC: 5833654. DOI: 10.1001/jamaoncol.2017.1617. View

17.

Skeate J, Otsmaa M, Prins R, Fernandez D, Da Silva D, Kast W . TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy. Front Immunol. 2020; 11:922. PMC: 7243824. DOI: 10.3389/fimmu.2020.00922. View

18.

Garcia-Gomez A, Rodriguez-Ubreva J, Ballestar E . Epigenetic interplay between immune, stromal and cancer cells in the tumor microenvironment. Clin Immunol. 2018; 196:64-71. DOI: 10.1016/j.clim.2018.02.013. View

19.

Carter S, Cibulskis K, Helman E, McKenna A, Shen H, Zack T . Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012; 30(5):413-21. PMC: 4383288. DOI: 10.1038/nbt.2203. View

20.

Xu Q, Zhang Z, Chen Z, Zhang B, Zhao C, Zhang Y . Nonspecific immunoglobulin G is effective in preventing and treating cancer in mice. Cancer Manag Res. 2019; 11:2073-2085. PMC: 6410752. DOI: 10.2147/CMAR.S188172. View